Meeting
2024 ASCO Genitourinary Cancers Symposium
Tumor suppressor genes (TSG), treatment, and survival in de novo metastatic hormone-sensitive prostate cancer.
Authors
Martin W. Schoen
St. Louis Veterans Affairs Medical Center, St. Louis, MO
Martin W. Schoen , Robert Bruce Montgomery , Eric Marshall Knoche
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 187)
DOI
10.1200/JCO.2024.42.4_suppl.187
Abstract #
187
Poster Bd #
H16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).
First Author: Oscar Reig Torras
Poster
2021 ASCO Annual Meeting
Association of androgen receptor signature and RB1, PTEN, TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.
First Author: Laura Ferrer-Mileo
Poster
2023 ASCO Annual Meeting
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
First Author: Mamta Parikh
Poster
2023 ASCO Annual Meeting
Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.
First Author: Anis Hamid